151 |
Implication of immune system in chondrosarcoma progression and therapeutic response : Could immunotherapy play a role in chondrosarcoma treatment ? / L’implication du système immunitaire dans la progression et la réponse thérapeutique du chondrosarcome : Est-ce que l’immunothérapie peut jouer un rôle dans le traitement du chondrosarcome ?Simard, François 14 June 2016 (has links)
Le chondrosarcome (CHS) est caractérisé par une grande chimio et radiorésistance ; il y a un besoin urgent de nouvelles stratégies thérapeutiques pour cette tumeur. Parmi celles-ci, certaines approches d'immunothérapie pourraient être d'un grand intérêt. Nous étudions actuellement l'implication du système immunitaire dans la progression du CHS et la réponse thérapeutique à la fois sur des échantillons humains et dans le modèle de chondrosarcome de rat (SRC).Dans le CHS humain et de rat, des infiltrats immunitaires composés de lymphocytes et macrophages ont été identifiés dans la zone péritumorale. L’infiltration immunitaire est en corrélation avec l’évolution de la tumeur (grade, envahissement et taille). L'expression de PD1 et PDL1 ont été détectée dans les infiltrats immunitaires et cellules tumorales du CHS chez l’homme et le rat. Le niveau d'expression PD-L1 en corrélation avec la survie des patients et le taux de rechute. Dans le model SRC, la déplétion sélective de lymphocytes T a entrainé une accélération de la progression tumorale, tandis que la déplétion de macrophages l’a ralenti. Les splénocytes isolés de rats porteurs de CHS ont montré une cytotoxicité spécifique dirigée contre les cellules de chondrosarcome (27%), qui a diminué de manière significative avec des rats appauvrie en CD3 (11%). La voie de signalisation PI3K/mTOR ne peut pas être associée à une immunothérapie car elle induit une action immunosuppressive in vivo.L'environnement immunitaire contribue à la progression du CHS à la fois chez l’homme et chez le rat, ce qui suggère que une approche immunomodulatrice avec des anticorps bloquant PDL1 pourrait être testée pour le CHS / Chondrosarcoma is highly resistant to chemotherapy and radiation and there is an urgent need in developing new therapeutic strategies for this malignancy; among these, some immunotherapy approaches could be of great interest. We are currently investigating the immune system implication in chondrosarcoma progression and therapeutic response both on human samples and in rat chondrosarcoma model (SRC). In human and rat chondrosarcoma, immune infiltrates composed of lymphocytes and macrophages were identified in the peritumoral area. Immune infiltrates composition was found correlated with tumors characteristics and evolution (grade, invasiveness and size). Expression of PD-1 and PD-L1 was detected in CHS immune infiltrates, both in human and rat (and on tumor cells). PD-L1 expression level correlated with patients survival and relapse rate. In SRC, T lymphocytes depletion resulted in an accelerated tumor progression, while CD163+ macrophages depletion slowed down tumor progression. Splenocytes isolated from CHS bearing SRC showed a specific cytotoxicity directed against chondrosarcoma cells (27%), which significantly decreased in CD3 depleted SRC (11%). The immune environment contributes to CHS progression in both human and animal models, this associated with expression of immune checkpoint PD1/PDL1 suggest that immunomodulatory approaches with PD-L1 blocking antibody could be applied in CHS; this approach is currently being tested in SRC
|
152 |
Étude de l'histoire évolutive des PI3K et des voies de signalisation associées / Evolutionary history of PI3Ks and related signalling pathwaysPhilippon, Héloïse 05 July 2016 (has links)
L'objectif principal de ma thèse a été la caractérisation de l'histoire évolutive des voies de signalisation au travers d'une double approche: (i) l'analyse phylogénétique de leurs composés; et (ii) l'identification et la caractérisation de leurs interactions par l'analyse des interactomes d'organismes modèles. Or, bien que de nombreux outils soient disponibles pour la reconstruction d'arbres de gènes individuels, peu de méthodes ont été développées pour l'étude d'un ensemble de protéines impliquées dans un même processus cellulaire. Pourtant, au sein de la cellule, la plupart des protéines agissent en interaction avec d'autres protéines. Dans un premier temps, j'ai étudié l'histoire évolutive de la famille des PI3K (Phosphatidylinositol 3-kinases). Cette première analyse phylogénétique détaillée m'a permis de mettre en place une méthodologie applicable aux voies de signalisation. Un problème important rencontré dans cette étude a consisté en la sélection de transcrits alternatifs et ceci m'a conduit à développer un logiciel dédié nommé BATfinder (\Best Aligned Transcript finder). Dans le but d'étudier la voie de signalisation AKT/mTOR, j'ai effectué l'implémentation de la méthodologie validée avec les PI3K. Cette implémentation a pris la forme d'un pipeline automatique nommé EPINe (Easy Phylogenetics for Interaction Networks). Ce pipeline est théoriquement utilisable pour l'analyse phylogénétique de tout réseau métabolique eucaryote / The main goal of my thesis was the characterization of the evolutionary history of signalling pathways through a twofold approach: (i) the phylogenetic analysis of their components; and (ii) the identification and characterization of their interactions by the analysis of model organisms interactomes. While many tools are available for single genes tree reconstruction, only a few methods have been developed for the study of a set of proteins involved in the same cellular process. However, inside the cell, most of proteins interact with others.Initially, I studied the evolutionary history of the PI3K family (Phosphati-dylinositol 3-kinases). This first detailed phylogenetic analysis allowed me to set up a methodology suitable for signalling pathways. One of the important problems encountered in this study was the selection of alternative transcripts and this led me to develop a software called BATfinder (Best Aligned Transcript finder ). In order to study the AKT/mTOR signalling pathway, I have implemented the methodology previously validated with PI3Ks. This implementation was carried out as an automated pipeline called EPINe (Easy Phylogenetics for Interaction Networks). This pipeline is theoretically usable for the phylogenetic analysis of any eukaryotic metabolic network
|
153 |
Remodelamento da matriz extracelular da medula óssea em desnutrição protéica: possível relação da via de AKT com a expressão de fibronectina e metaloproteinases de matriz / Extracellular matriz remodeling of the bone marrow in protein malnutrition: possible relationship of AKT pathway with expression of fibronectin and matriz metalloproteínases.Graziela Batista da Silva 26 April 2016 (has links)
A desnutrição proteica (DP) pode ocasionar alterações na matriz extracelular (MEC) de diferentes órgãos e tecidos, inclusive o hematopoético, com comprometimento funcional. Estudos do nosso laboratório demonstraram, em modelo murino de DP, aumento da expressão proteica de fibronectina (FN) no estroma medular ósseo in vivo, principalmente na região subendosteal (local de fixação da célula tronco progenitora hemopoética). Já in vitro, no estroma medular ósseo, observou-se tanto o aumento quanto a diminuição de FN e a presença de suas isoformas. Essas alterações de FN parecem estar envolvidas com a hipoplasia da medula óssea (MO) em camundongos desnutridos. As modificações quantitativas de FN podem ser devidas: (i) à ação das metaloproteinases de matriz (MMP) responsáveis pela degradação das proteínas da MEC; (ii) aos inibidores de metaloproteinases (TIMP) que regulam a degradação da MEC; (iii) às alterações transcricionais, reguladas pela via de AKT/mTOR, que controla os splicing alternativos na FN, resultando em isoformas dessa proteína; (iv) a processos pós-transcricionais modulados por LC3, que aumenta a tradução do RNAm de FN. Assim, o objetivo deste estudo foi elucidar os mecanismos que alteram o turnover de FN no estroma medular ósseo em modelo murino de DP. Utilizamos camundongos, C57BL/6J machos, adultos, separados em dois grupos: controle e desnutrido, alimentados, ad libitum, com ração contendo 12% e 2% de proteína, respectivamente. Após cinco semanas de indução à desnutrição os camundongos foram eutanasiados, e coletado o material biológico. Avaliamos: o estado nutricional, o hematológico, a histologia da MO femoral bem como a determinação imunohistoquímica da FN, MMP-2 e MMP-9, determinação da expressão de FN e suas isoformas em células totais da MO, o estabelecimento do estroma medular ósseo in vitro, por 28 e 35 dias de cultivo. A partir das culturas foram avaliadas a expressão de RNAm de FN e suas isoformas, MMP-2, MMP-9, TIMP-1, TIMP-2, AKT, mTOR e LC3α e β, quantificação de MMP-2, MMP-9, TIMP-1, TIMP-2,TNFα, TGFβ e IL-1β e determinação de LC3β e proteínas da via de AKT/mTOR. Não observamos alterações na expressão do RNAm de FN e suas isoformas ex vivo e in vitro, mas um aumento da deposição de FN na MO.Também não observamos modificações na imunolocalização de MMP-2 e MMP-9 na MO e na atividade dessas proteínas no sobrenadante de culturas de células estromais in vitro, mas houve aumento da expressão do RNAm de MMP-9 em 28 dias de cultivo. Não detectamos alterações na expressão de RNAm e na concentração de TIMP-1 e TIMP-2 no sobrenadante das culturas. Houve redução significativa de TNFα e TGFβ no sobrenadante das culturas de 28 dias. Observamos aumento da expressão do RNAm de mTOR em culturas de 28 dias e LC3α e LC3β em 35 dias de células estromais. Encontramos menor fosforilação de PI3K, AKT, PTEN, mTOR e mTOR total e aumento de LC3β em culturas de 28 dias, mas redução de LC3β em 35 dias. Em função dos dados inferimos que a DP conduz a alterações da FN que não estão relacionadas à ação de MMPs e TIMPs e sim a modificações de LC3β e da via de AKT/mTOR. / Protein malnutrition (PM) can lead changes in extracellular matrix (ECM) from several organs and tissues, including hematopoietic, with functional impairments. Research from our laboratory demonstrated, in a murine model of protein malnutrition, increase in proteic expression of fibronectin (FN) in vivo bone marrow stroma, principally in subendosteal region (attachment site of hematopoietic stem/progenitor cell - HSPC). It was observed as both an increase and a decrease in the presence of FN and its isoforms in vitro bone marrow stroma. These FN changes seem to be related to bone marrow (BM) hypoplasia in malnourished mice. Quantitative FN changes may be due to: (i) action of matrix metalloproteinases (MMP) responsible for ECM proteins degradation; (ii) tissue inhibitors of metalloproteinases (TIMP) that regulate ECM degradation; (iii) transicional changes regulated by AKT/mTOR pathway, which controls alternative splicing in FN, resulting in isoforms from this protein; (iv) post-transcriptional processes modulated by LC3 that increases FN mRNA translation. Therefore, the aim of this study was to elucidade the mechanisms that changes the FN turnover in bone marrow stroma in a murine model of PM. C57BL/6J, adult and male mice were used and divided into two groups: control and malnourished, fed ad libitum with ration containing 12% and 2% of protein, respectively. After five weeks of induction malnutrition, mice were euthanized and the biological material was collected. We evaluated: nutritional and hematologic status, the femoral BM histology, immunohistochemistry determination of FN, MMP-2 and MMP-9, the FN and its isoforms expression determination in total BM cells, establishment of in vitro bone marrow stroma for 28 and 35 days of culture. From the cultures were evaluated FN mRNA expressions and its isoforms, MMP-2, MMP-9, TIMP-1, TIMP-2, AKT, mTOR, LC3α and β, quantification of MMP-2, MMP-9, TIMP-1, TIMP-2,TNFα, TGFβ and IL-1β and determination of LC3β and AKT/mTOR proteins. No changes were observed, ex vivo and in vitro, in the expression of FN mRNA and its isoforms, but there was a FN deposition increase in BM. We did not observe modifications in MMP-2 e MMP-9 immunolocalization in BM and in these proteins activity in the supernatant of in vitro stromal cell culture, but there was an increase in MMP-9 mRNA expression after 28 days of culture. We did not detect changes in mRNA and in TIMP-1 and TIMP-2 expressions in the supernatant of cultures. There was significant reduction of TNFα and TGFβ in the cultures supernatant of 28 days. We observed an increase of mTOR RNAm in 28 days cultures and also LC3α and LC3β in stromal cells with 35 days. We found lower phosphorylation of PI3K, AKT, PTEN, mTOR e total mTOR and an LC3β increase in 28 days cultures, yet an LC3β reduction in 35 days. According to the data we conclude that PM leads to FN changes that are not related to MMPs and TIMPs actions, but the LC3β and AKT/mTOR pathway modifications.
|
154 |
Análise da expressão e mecanismos de ação das proteínas Akt, Hsp90, mTOR e ciclina D1 em cultura de células de carcinoma epidermoide humano e células displásicas após irradiação com laser em baixa intensidade / The expression and action mechanisms of Akt, Hsp90, mTOR and cyclin D1 proteins in cultured cells of squamous cell carcinoma and dysplastic cells after being irradiated with low level laser therapyFelipe Fornias Sperandio 06 December 2012 (has links)
O carcinoma de cabeça e pescoço é uma neoplasia maligna de origem epitelial que resulta em aproximadamente 500.000 novos casos por ano ao redor do mundo. Diversos estudos têm sido conduzidos de maneira a elucidar os mecanismos de proliferação e invasão desta doença, sendo a via de sinalização Akt/mTOR e proteínas relacionadas, apontada como uma das principais vias envolvidas em sua progressão. Sabe-se que células neoplásicas, bem como células de diferentes tecidos, podem ter seu comportamento modificado após terem sido irradiadas com laser em baixa intensidade (LLLT). Porém, os mecanismos de atuação da luz laser de baixa potência sobre estas células permanecem ainda não completamente esclarecidos. Portanto, o objetivo deste estudo foi o de analisar a viabilidade celular e expressão das proteínas Akt, pAkt, Hsp90, S6, pS6 e Ciclina D1 em duas linhagens celulares de carcinoma de boca (SCC9 e SCC25), bem como em uma linhagem de queratinócitos orais humanos com displasia (DOK) após irradiação com laser em baixa intensidade. O laser utilizado foi um diodo semicondutor de arseneto de Gálio e Alumínio (GaAlAs) operando nos comprimentos de onda vermelho (660nm) e infravermelho (780nm), com potência fixa em 40mW e três densidades de energia para cada comprimento de onda disponível: 2.05J/cm², 3.07J/cm² e 6.15J/cm². A análise de apoptose foi realizada por meio do teste de TUNEL e a expressão proteica foi obtida com imunofluorescência e western blotting. Após análise estatística por meio do método ANOVA dois critérios e testes de Tukey ou teste T de estudante, todos com nível de significância de 5%, pôde-se concluir que a LLLT induziu comportamentos distintos em cada uma das linhagens celulares utilizadas. Foi notado aumento, bem como diminuição da viabilidade celular, dependendo do comprimento de onda utilizado e das células irradiadas. A densidade de energia de 2.05J/cm² foi a que produziu efeitos mais significativos em SCC9. Para a linhagem celular SCC25, a dose mais relevante foi a de 3.07J/cm², enquanto que para a linhagem DOK, a dose de 6.15J/cm² causou efeitos mais proeminentes. Estas respectivas doses foram escolhidas para cada uma das linhagens para dar continuidade aos experimentos de Western Blotting e Imunofluorescência. Dentre os resultados mais relevantes obtidos com estas técnicas, pode-se citar a variação dos níveis de pS6 e Ciclina D1 para a linhagem DOK em determinados períodos. Já a linhagem SCC9 apresentou variação dos níveis de pAkt e Ciclina D1 nos períodos estudados. A linhagem SCC25 também teve as expressões de pAkt, pS6 e Ciclina D1 modificadas por LLLT. De maneira interessante, o aparecimento ou manutenção de uma isoforma de Hsp90 foi encontrado em SCC9 e SCC25 após irradiação laser. Por fim, a indução de apoptose foi detectada na linhagem SCC25. Em conclusão, pode-se dizer que a LLLT, como empregada neste estudo, foi capaz de aumentar a expressão de proteínas relacionadas à progressão e invasão em todas as linhagens estudadas. Além disso, a irradiação laser foi única, apesar de ter causado efeitos prolongados, algumas vezes até o último período estudado. / Head and neck squamous cell carcinoma (HNSCC) is an epithelial malignant neoplasm that accounts for approximately 500.000 new cases yearly around the world. Several studies have been conducted to elucidate the mechanisms of proliferation and invasion of this lesion, whereas the Akt/mTOR signaling pathway with its related proteins is being pointed out as one of the main pathways involved in HNSCC`s progression. Neoplastic cells, as well as cells that originate from different tissues may have their behavior modified by low level laser therapy (LLLT); however, the mechanisms through which the low level laser light interacts with these cells remain poorly understood. Thus, this study sought to evaluate the cell viability and the expression levels of Akt, pAkt, Hsp90, S6, pS6 and Cyclin D1 proteins in two oral squamous cell carcinoma cell lineages (SCC9 and SCC25) and in one oral dysplastic human keratinocyte cell line (DOK) after they had been treated with LLLT. The laser device was a semiconductor diode of Gallium and Aluminum Arsenate (GaAlAs), operating with wavelengths of 660nm (red) and 780nm (infrared), with a fixed power of 40mW and giving three different energy densities: 2.05J/cm², 3.07J/cm² and 6.15J/cm². Apoptosis was analyzed through TUNEL test and the protein expression was accessed with Immunofluorescence and Western blotting. After statistical analysis through two-way ANOVA and Tukey or Student`s T test, all of them with a level of significance of 5%, it was concluded that LLLT induced distinct behaviors to each of the studied cell lines. Increases and inhibitions in cell viabilities were detected depending on the wavelength and also on the irradiated cell line. The energy density of 2.05J/cm² produced the most significant findings over SCC9. On the other hand, in SCC25 the most relevant results were detected with 3.07J/cm², while the most prominent findings were seen with 6.15J/cm² when the cell line DOK was evaluated. In that way, these respective doses were chosen for each cell line to continue with Western blotting and Immunofluorescence. Among the most relevant findings, the variation of pS6 and Cyclin D1 levels can be cited for DOK in some evaluated periods. SCC9 presented both pAkt and Cyclin D1 variations in the studied periods. Besides that, SCC25 also had pAkt, pS6 and Cyclin D1 levels modified by LLLT. Interestingly, the appearance and maintenance of an Hsp90 isoform was found in SCC9 and SCC25 after laser irradiation. Moreover, the induction of apoptosis was detected for the SCC25 cell line. Finally, the LLLT employed herein was able to enhance the expression of proteins related to progression and invasion in all of the studied cell lines. In addition, there was a single laser irradiation, although it caused prolonged effects, sometimes through the latest evaluated period.
|
155 |
O papel da via mammalian target of rapamycin (mTOR) no desenvolvimento da cardiomiopatia séptica induzida por ligadura e perfuração do ceco / The role of the mammalian target of rapamycin (mTOR) pathway in the development of septic cardiomyopathy induced by cecal ligation and punctureAna Caroline Silva de Freitas 05 April 2018 (has links)
A disfunção cardíaca, decorrente de um prejuízo na contratilidade miocárdica, tem sido reconhecida como um fator importante que contribui para as altas taxas de mortalidade na sepse. Outro fato importante aponta para o envolvimento das calpaínas na inibição da via de sinalização PI3K/mTOR levando a uma diminuição potencial das taxas globais de síntese proteica através da redução da maquinaria de tradução disponível, o que reforça o envolvimento destes elementos na progressão da disfunção cardíaca na sepse. Metodologia: Foram utilizados camundongos da linhagem C57/BL6 para indução de sepse através da técnica de ligadura e perfuração do ceco separados em quatro grupos: controle com e sem tratamento e sepse moderada com e sem tratamento, o tratamento foi realizado 2 horas antes da cirurgia com inibidor da via mTOR, rapamicina. Foi realizada análise histopatológica em metacrilato e coloração picrosirius para colágeno, western blotting para quantificação da expressão proteica e real-time PCR para quantificação da expressão gênica, por fim realizamos análise funcional através da ecocardiografia. Resultados: Foi encontrado aumento das lesões teciduais e depósito de colágeno no grupo séptico tratado com rapamicina. A análise por western blotting e real-time PCR demonstrou redução das proteínas envolvidas na via mTOR nos grupos sépticos com e sem tratamento com ênfase no grupo tratado e por fim a avaliação funcional mostrou redução dos parâmetros débito cardíaco e fração de ejeção nos grupos sépticos com e sem tratamento. Conclusão: Nossos resultados demonstram que a via mTOR é de extrema importância na estrutura e função cardíacas, visto que sua inibição ocasionou o aumento de lesões e deposição de colágeno juntamente com alterações funcionais, podendo se transformar em um possível alvo terapêutico para futuras pesquisas clínicas em animais e humanos. / Cardiac dysfunction, due to impairment in myocardial contractility, has been recognized as an important factor contributing to the high mortality rates in sepsis. Another important fact is the involvement of the calpain in the inhibition of the PI3K / mTOR signaling pathway leading to a potential decrease in the overall rates of protein synthesis through the reduction of available translation machinery, which reinforces the involvement of these elements in the progression of cardiac dysfunction in sepsis. Methods: C57 / BL6 mice were used for induction of sepsis through the technique of ligation and perforation of the cecum separated into four groups: control with and without treatment and moderate sepsis with and without treatment, treatment was performed 2 hours before surgery with mTOR pathway inhibitor, rapamycin. Histopathological analysis was performed on methacrylate and picrosirius staining for collagen, western blotting for quantification of protein expression and real-time PCR for quantification of gene expression. Finally we performed functional analysis through echocardiography. Results: Increased tissue lesions and collagen deposition were found in the septic group treated with rapamycin. Western blotting and real-time PCR analysis showed reduction of the proteins involved in the mTOR pathway in the septic groups with and without treatment with emphasis in the treated group and finally the functional evaluation showed a reduction of the parameters cardiac output and ejection fraction in the septic groups with and without treatment. Conclusion: Our results demonstrate that the mTOR pathway is extremely important in cardiac structure and function, since its inhibition has resulted in increased lesions and collagen deposition along with functional alterations, and may become a possible therapeutic target for future clinical research in animals and humans.
|
156 |
A ativação constitutiva de mTORC1 em adipócitos aumenta a capacidade oxidativa mitocondrial e reduz a adiposidade visceral em camundongos. / Constitutive adipocyte mTORC1 activation enhances mitochondrial oxidative capacity and reduces visceral adiposity in mice.Magdalon, Juliana 12 September 2016 (has links)
A atividade do complexo 1 da proteína alvo mecanístico da rapamicina (mTORC1), importante regulador da adiposidade e do metabolismo de lipídeos, está aumentada no tecido adiposo de camundongos obesos. A inibição completa de mTORC1 reduz a adiposidade, enquanto que sua inibição parcial potencializa a obesidade induzida por dieta. Assim, hipotetizamos que um nível ótimo de ativação de mTORC1 é necessário para promover aumento da adiposidade, de forma que sua superativação é tão inibitória para a deposição de gordura quanto sua inibição completa. Para testar esta hipótese, investigamos os efeitos da ativação constitutiva de mTORC1, induzida pela deleção de Tsc1, especificamente em adipócitos na adiposidade in vivo. A deleção de Tsc1 reduziu a massa do tecido adiposo visceral, mas não do subcutâneo, que foi associado ao aumento da lipólise e browning. Além disso, aumentou em ambos tecidos adiposos a massa e atividade oxidativa mitocondrial. Esses dados apoiam nossa hipótese de que é necessário um nível ótimo de ativação de mTORC1 para promover aumento da adiposidade. / The activity of mechanistic target of rapamycin complex 1 (mTORC1), an important regulator of adiposity and lipid metabolism, is increased in adipose tissue of obese mice. Complete mTORC1 inhibition reduces adiposity, whereas partial mTORC1 inhibition enhances diet-induced obesity. Therefore, we hypothesized that an optimal level of mTORC1 activity is required to increase adiposity, in such a manner that mTORC1 overactivation is as inhibitory to fat deposition as its complete inhibition. To test this hypothesis, we investigated the effects of constitutive mTORC1 activation, induced by Tsc1 deletion, specifically in adipocytes on adiposity in vivo. Tsc1 deletion reduced visceral, but not subcutaneous, fat mass, which was associated with increased lipolysis and browning. Moreover, it enhanced mitochondrial mass and oxidative activity in both visceral and subcutaneous fat. These data support our hypothesis that an optimal level of mTORC1 activation is necessary to increase adiposity.
|
157 |
Prise en charge des thymomes chez l'homme : développement de cultures de cellules épithéliales dérivées de tumeurs pour la compréhension des dérégulations de la cellule tumorale / Management of human thymomas : development of thymic epithelial cell cultures derived from tumors for the understanding of tumoral cells dysregulationMaury, Jean-Michel 23 May 2019 (has links)
Les tumeurs épithéliales thymiques (TET) humaines sont rares (250 - 300 cas/an en France). On distingue les thymomes de type A, AB ou B d'évolution lente avec une survie actuarielle > 95% à 5 ans pour les stades précoces et les carcinomes thymiques d'évolution plus sévère avec une survie actuarielle à 5 ans < 20% pour les stades IV. La pierre angulaire du traitement des TET est l'exérèse chirurgicale complète, facteur pronostique le plus significatif identifié à ce jour. Les récidives des TET, essentiellement pleurales pour les thymomes et générales pour les carcinomes thymiques, sont de prise en charge complexe. Les avancées thérapeutiques sont limitées notamment par l'absence de modèles d'étude de la cellule épithéliale thymique tumorale. Dans le cadre d'une prise en charge multidisciplinaire des récidives pleurales métastatiques, nous avons développé la pleurectomie de cytoréduction associée à une chimio hyperthermie (cisplatine/ mitomycine ; 42°C) intra thoracique (CHIT) pour la prise en charge des métastases pleurales de thymome. Chez des patients sélectionnés (n=19), la médiane de survie sans récidive était de 53 mois et les survies actuarielles à 1 an et 5 ans étaient respectivement de 93% et 86%. Cette technique chirurgicale innovante a permis de développer une alternative à la morbide pleuro pneumonectomie. L'efficacité de la CHIT pose des questions sur le rôle de l'hyperthermie et sur le type de chimiothérapie à associer. Avec pour objectif d'améliorer la prise en charge des patients, la connaissance de la biologie tumorale thymique et l'identification de potentielles cibles thérapeutiques sont des voies de recherche importantes pour améliorer la survie des patients. Nous avons développé des cultures de cellules épithéliales thymiques dérivées in vitro de 12 TET (11 thymomes A, AB ou B et un carcinome thymique), caractérisées par leur potentiel prolifératif et leur expression de cytokératine. La voie PI3K / Akt / mTOR joue un rôle clé dans de nombreux cancers ; plusieurs études de phases I / II ont rapporté un effet positif des inhibiteurs de mTOR pour le contrôle de l'évolution du thymome chez les patients. Nous avons mis en évidence l'expression et l'activation des effecteurs mTOR, Akt et P70S6K dans les thymomes et dans les cellules épithéliales thymiques dérivées in vitro. Nous avons montré l'efficacité de la rapamycine, inhibiteur de mTOR, à réduire la prolifération cellulaire (30%) sans induire de mort cellulaire. Nos résultats suggèrent que l'activation de la voie Akt / mTOR participe à la prolifération cellulaire associée à la croissance tumorale. Nous avons établi un nouvel outil permettant l'étude de la dérégulation cellulaire au cours des thymomes. Dans un contexte de tumeurs rares, ces cellules permettront d'aborder des études mécanistiques in vitro et de tester l'efficacité de drogues anti tumorales / Human thymic epithelial tumors (TETs) are rare (250 – 300 cases/ year in France). We distinguish thymomas (A, AB and B subtypes) with indolent evolution (5 years actuarial survival in early stages >95%) and more aggressive thymic carcinomas (5 years actuarial survival <20% in stage IV). Surgical complete resection when feasible is the corner stone of a multimodal therapy and the most significant factor on survival. Relapse of TETs principally in pleura for thymomas (75%) and general for thymic carcinomas are difficult to treat. Therapeutics advances are limited given the lack of studies models of tumoral thymic epithelial cell. In a multidisciplinary approach for the treatment of metastatic pleural relapse of thymomas we developed an innovative surgical technique: cytoreductive pleurectomy associated with hyper thermic intra pleural chemotherapy (Cysplatin/ Mitomycin; 42°C) (ITCH). In selected patient (n=19), ITCH provides an efficient alternative to the morbid pleuro pneumonectomy. The median of free disease survival was 53 months, one year and five years actuarial survival were respectively 93% and 86%. However, the effectiveness of ITCH procedure questions on the played role ok hyperthermia, on the choice of chemotherapy association. With the aim to improve TETs therapies, the knowledge of TETs biology to identify potential target therapies is currently challenging. We developed an in vitro study model of tumoral thymic epithelial cells derived from 12 TETs (11 A, AB and B thymomas and one thymic carcinoma) characterized by their proliferative abilities and the cytokeratin expression. The PIK3 / Akt / mTOR pathway is implicated in numerous cancers. Several phase I, II studies advocate the potential role of mTOR inhibitors in the control of the metastatic disease. We highlighted the expression and the activation of mTOR, Akt and P70S6K effectors in TETs and in thymic epithelial cells in vitro derived. We showed the efficacy of rapamycin (mTOR inhibitor) in the inhibition (-30%) of in vitro cell proliferation without cell death induction. Our results suggest the implication of the PIK3 / Akt / mTOR pathway in the tumoral cell growth. We established a new tool to study cell dysregulation in TETs. In the context of rare tumors, these cells could allow in vitro mechanistic studies and test the efficacy of new anti tumoral therapies
|
158 |
Einfluss von Rapamycin auf Myelinmissbildungen in einem Mausmodel einer tomakulösen Neuropathie / Influence of Rapamycin to Myelin Abnormalities in a Mouse-Model of a Tomaculous NeuropathieWolfer, Susanne 05 February 2010 (has links)
No description available.
|
159 |
mTOR Inhibitors and Calcineurin Inhibitors Do Not Affect Adhesion Molecule Expression of Human Macro- and Microvascular Endothelial CellsLehle, Karla, Schreml, Stephan, Kunz-Schughart, Leoni A., Rupprecht, Leopold, Birnbaum, Dietrich E., Schmid, Christof, Preuner, Jürgen G. 27 February 2014 (has links) (PDF)
We examined the effect of cyclosporin A, tacrolimus, sirolimus and everolimus on the cell growth, viability, proliferation, expression of cellular adhesion molecules (CAM) and leukocyte (PBMC) binding of human macrovascular (coronary artery, saphenous vein) and microvascular endothelial cells (EC). Tacrolimus did not affect EC integrity, growth or expression of CAM. Exclusively, EC from the coronary arteries showed a reduced cellular growth (about 30%) under cyclosporin A and tacrolimus treatment. In contrast, treatment with mTOR inhibitors reduced EC proliferative activity by about 40%, independently of the EC origin. No induction of apoptosis (caspase-3/7 activity) or cytotoxicity (MTS test) was observed. Long-term treatment with high concentrations of sirolimus and everolimus did not enhance the expression of CAM. Stimulation with tumor necrosis factor significantly increased the expression of CAM, independently of the drugs used. None of the mTOR inhibitors influenced the tumor necrosis factor-induced expression of CAM, whereas adhesion of PBMC increased significantly, as described by other papers. In summary, neither calcineurin inhibitors nor mTOR inhibitors activate human micro- and macrovascular EC. Therefore, the investigated drugs are unlikely to contribute to EC activation during transplant-associated vasculopathy. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
|
160 |
Essai du traitement pré-clinique du carcinome hépatocellulaire sur la cirrhose dans le modèle de rat / Pre-trial of hepatocellular carcinoma on cirrhosis in a rat modelZeybek, Ayça 22 December 2016 (has links)
Hepatocellular carcinoma (HCC) is the second most common cause of cancerrelated mortality worldwide. AKT pathway has been found activated in 50% of HCC cases, making it promising target. Therefore we assess efficacy of the allosteric AKT inhibitor or the combination of Sorafenib with AKT inhibitor compared to untreated control and to standard treatment, Sorafenib, in vitro and in vivo. AKT inhibitor blocked phosphorylation of AKT in vitro and strongly inhibited cell growth with significantly higher potency than Sorafenib. Similarly, apoptosis and cell migration were strongly reduced by AKT inhibitor in vitro. To mimic human advanced HCC, we used diethylnitrosamine-induced cirrhotic rat model with fully developed HCC. MRI analyses showed that AKT inhibitor significantly reduced overall tumor size. Furthermore, number of tumors was decreased by AKT inhibitor, which was associated with increased apoptosis and decreased proliferation. Tumor contrast enhancement was significantly decreased in the AKT inhibitor group. Moreover, on tumor tissue sections, we observed a vascular normalization and a significant decrease in fibrosis in surrounding liver of animals treated with AKT inhibitor. Finally, pAKT/AKT levels in AKT inhibitor treated tumors were reduced, followed by down regulation of actors of AKT downstream signalling pathway: pmTOR, pPRAS40, pPLCγ1 and pS6K1. In conclusion, we demonstrated that AKT inhibitor blocks AKT phosphorylation in vitro and in vivo. In HCC-rat model, AKT inhibitor was well tolerated, showed anti-fibrotic effect and had stronger antitumor effect than Sorafenib. Our results confirm the importance of targeting AKT in HCC. / Hepatocellular carcinoma (HCC) is the second most common cause of cancerrelated mortality worldwide. AKT pathway has been found activated in 50% of HCC cases, making it promising target. Therefore we assess efficacy of the allosteric AKT inhibitor or the combination of Sorafenib with AKT inhibitor compared to untreated control and to standard treatment, Sorafenib, in vitro and in vivo. AKT inhibitor blocked phosphorylation of AKT in vitro and strongly inhibited cell growth with significantly higher potency than Sorafenib. Similarly, apoptosis and cell migration were strongly reduced by AKT inhibitor in vitro. To mimic human advanced HCC, we used diethylnitrosamine-induced cirrhotic rat model with fully developed HCC. MRI analyses showed that AKT inhibitor significantly reduced overall tumor size. Furthermore, number of tumors was decreased by AKT inhibitor, which was associated with increased apoptosis and decreased proliferation. Tumor contrast enhancement was significantly decreased in the AKT inhibitor group. Moreover, on tumor tissue sections, we observed a vascular normalization and a significant decrease in fibrosis in surrounding liver of animals treated with AKT inhibitor. Finally, pAKT/AKT levels in AKT inhibitor treated tumors were reduced, followed by down regulation of actors of AKT downstream signalling pathway: pmTOR, pPRAS40, pPLCγ1 and pS6K1. In conclusion, we demonstrated that AKT inhibitor blocks AKT phosphorylation in vitro and in vivo. In HCC-rat model, AKT inhibitor was well tolerated, showed anti-fibrotic effect and had stronger antitumor effect than Sorafenib. Our results confirm the importance of targeting AKT in HCC.
|
Page generated in 0.0195 seconds